- Home
- ASAN vs VRDN Comparison
ASAN vs VRDN Comparison
Compare ASAN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | VRDN |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASAN | VRDN |
|---|---|---|
| Price | $12.97 | $31.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $16.58 | ★ $41.17 |
| AVG Volume (30 Days) | ★ 3.0M | 1.5M |
| Earning Date | 12-02-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $773,570,000.00 | $70,789,000.00 |
| Revenue This Year | $11.38 | $26,257.62 |
| Revenue Next Year | $8.51 | $10.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.47 | ★ 23340.07 |
| 52 Week Low | $11.58 | $9.90 |
| 52 Week High | $24.50 | $34.04 |
Technical Indicators
Market Signals| Indicator | ASAN | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 54.36 |
| Support Level | $12.78 | $29.63 |
| Resistance Level | $13.62 | $31.47 |
| Average True Range (ATR) | 0.47 | 1.06 |
| MACD | -0.11 | -0.28 |
| Stochastic Oscillator | 14.56 | 64.62 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).